• Sitagliptin Phosphate Monohydrate: Translating DPP-4 Inhibit

  2026-05-30

  This thought-leadership article explores the mechanistic, translational, and strategic landscape of Sitagliptin phosphate monohydrate as a DPP-4 inhibitor, synthesizing new evidence on gastrointestinal mechanosensation, incretin hormone modulation, and preclinical metabolic models. We provide actionable guidance for researchers aiming to advance type II diabetes treatment research and highlight how APExBIO’s Sitagliptin phosphate monohydrate empowers the next wave of experimental and clinical innovation.

• Bestatin (Ubenimex) in Bench Research: Protocols & Pitfalls

  2026-05-29

  Bestatin (Ubenimex) stands out as a uniquely selective aminopeptidase inhibitor, enabling precision dissection of protease signaling and multidrug resistance mechanisms in both plant and mammalian systems. This guide translates bench-proven workflows, advanced troubleshooting, and actionable protocol enhancements into reproducible experimental success.

• Olive Biophenols Attenuate Aβ42-Induced Pathology in AD Mode

  2026-05-29

  This study demonstrates that olive biophenols, especially oleuropein, significantly reduce amyloid β-peptide (Aβ42)-induced neurotoxicity and plaque deposition in vitro and in vivo. The findings support the therapeutic potential of plant-derived compounds for targeting amyloid aggregation and oxidative stress in Alzheimer's disease.

• CTDNEP1-NEP1R1 Complex: Differential Roles in ER Lipid Regul

  2026-05-28

  This study uncovers how the stability and regulatory actions of CTD-nuclear envelope phosphatase 1 (CTDNEP1) in mammalian ER lipid metabolism depend on its interaction with the regulatory subunit NEP1R1. The findings refine our understanding of how ER membrane synthesis and lipid storage are differentially controlled, with implications for dissecting lipid homeostasis mechanisms in cell biology.

• 5-Azacytidine: Strategic Epigenetic Modulation for Translati

  2026-05-28

  This thought-leadership article explores the mechanistic and translational potential of 5-Azacytidine (5-AzaC) as a DNA demethylation agent in cancer and regenerative research. Integrating insights from recent studies on epigenetic regulation—such as the role of UHRF1-mediated DNA methylation in impaired osteogenesis—the article delivers actionable guidance for translational researchers. It also contextualizes APExBIO’s 5-Azacytidine within the competitive landscape, provides protocol parameters, and outlines future directions for leveraging DNA methylation modulators beyond oncology.

• Polymyxin B Sulfate: Applied Protocols for Infection Models

  2026-05-27

  Polymyxin B sulfate is a precision tool for Gram-negative infection research, uniquely enabling high-fidelity sepsis, immune maturation, and microbiome-modulating workflows. This guide delivers actionable protocols, troubleshooting, and advanced applications that empower researchers to leverage APExBIO's high-purity Polymyxin B (sulfate) for robust, reproducible results.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride: NHE1 Inhibition &

  2026-05-27

  5-(N,N-dimethyl)-Amiloride hydrochloride is a potent Na+/H+ exchanger inhibitor with high selectivity for NHE1, NHE2, and NHE3 isoforms. It enables precise control of intracellular pH regulation and has demonstrated protective effects in cardiac ischemia-reperfusion models. The compound, supplied as a hydrochloride salt by APExBIO, is pivotal in translational research focused on ion transport and endothelial injury.

• ABT-888 (Veliparib): Precision DNA Repair Inhibition in MSI

  2026-05-26

  Explore the mechanistic depth of ABT-888 (Veliparib) as a selective PARP inhibitor for advanced DNA repair inhibition in microsatellite instability (MSI) tumor research. This article offers a practical, evidence-driven guide for optimizing combination therapies and experimental design.

• Toremifene in Breast Cancer: 20 Years of Data and Research I

  2026-05-26

  This review synthesizes two decades of clinical and laboratory data on toremifene as a selective estrogen receptor modulator for hormone-sensitive breast cancer. The findings highlight the evolution of endocrine therapy, the importance of personalized biomarker-driven approaches, and avenues for integrating steroidal aromatase inhibitors into translational research.

• Dantrolene Sodium Salt: Precision Ryanodine Receptor Antagon

  2026-05-25

  Dantrolene sodium salt delivers unrivaled control over ryanodine receptor-mediated calcium release, enabling advanced genome editing and disease modeling. This guide details validated workflows, troubleshooting strategies, and protocol parameters for maximizing reproducibility and data quality in calcium signaling and DNA repair pathway studies.

• Fucoidan Mitigates Irinotecan-Induced Steatohepatitis via th

  2026-05-25

  This study reveals how irinotecan (CPT-11)-induced steatohepatitis is mediated by gut barrier dysfunction and neutrophil extracellular trap formation. The authors demonstrate that fucoidan restores gut-liver axis integrity, reduces hepatic inflammation, and may offer a targeted strategy to prevent chemotherapy-associated liver injury.

• Pericyte-Targeted Prodrug Strategy to Overcome VDA Resistanc

  2026-05-24

  This study introduces an enzyme-activated prodrug that selectively targets pericytes in the tumor microenvironment, overcoming resistance to traditional vascular disrupting agents (VDAs). The strategy leverages fibroblast activation protein α (FAPα) specificity to disrupt tumor vasculature, leading to improved tumor regression and offering new directions for cancer therapy.

• Topotecan Mechanisms and Clinical Insights for Oncology Rese

  2026-05-23

  This article reviews the key innovations, mechanisms, and clinical findings of topotecan as a topoisomerase I inhibitor in cancer therapy, based on Kollmannsberger et al.'s comprehensive study. The paper sheds light on topotecan’s unique pharmacological properties, efficacy in solid tumors, and its relationship with established agents like cisplatin. Implications for combination therapies and experimental modeling are discussed for translational oncology researchers.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride in Endothelial Assa

  2026-05-22

  5-(N,N-dimethyl)-Amiloride hydrochloride empowers precise studies of Na+/H+ exchanger function, intracellular pH dynamics, and endothelial injury. Its selectivity and potency make it essential for dissecting cellular mechanisms underlying cardiac and vascular dysfunction, as recently exemplified by moesin biomarker research.

• Canagliflozin in Preclinical Metabolic Disease Models: Proto

  2026-05-22

  Explore how Canagliflozin, a potent SGLT2 inhibitor, advances preclinical diabetes and kidney research by modulating renal glucose reabsorption and mitochondrial function. This article uniquely focuses on practical assay choices and protocol design for translational metabolic studies.

15811 records 1/1055 page Next 12345 下5页 Last page